NON-ENHANCING/MINIMALLY ENHANCING GLIOMAS: CAN WE IDENTIFY LOW GRADE GLIOMAS?

Abstract AIMS Gliomas are traditionally separated into low-grade (LGG) and high-grade (HGG). As LGG slower growing with pressures on operating capacity, there is an argument that surgery for these patients can wait. Pre- operatively, contrast enhancement imaging usually taken as the method of differentiating grade, belief absence indicates LGG. We therefore assessed minimal/non- enhancing tumours compared factors at diagnosis final histological outcome. METHOD identified a cohort over 19-month period first presentation to neurosurgical oncology clinic minimal/patchy/scattered foci (ME) or no areas (NE) imaging, collecting outcome using electronic patient records. RESULTS Of 60 identified, 53.3% were HGG, 35.0% 11.7% non-glioma. In NE HGG rates equal (43.3%), whereas in ME comprised 63.3% versus 26.7% older average than (median age 53 years 33 years) more prevalent males (62.95%) females (45.45%). formed majority presenting seizure only (60%), neurological deterioration (50%) ≥2 symptoms (57.6%), was higher presentations headache (66.7%) none (66.7%). CONCLUSIONS It not possible differentiate between ‘high-grade’ ‘low-grade’ gliomas based findings alone. Age clearly factor, but do appear be. working develop methods better pre-operatively.